Lyell Immunopharma's Ronde-Cel Achieves 77% Complete Response Rate in Pivotal Lymphoma Trial
Bitget2026/11/04 14:11- Lyell Immunopharma will present updated ronde-cel lymphoma trial results at the American Society of Hematology meeting, December 12-15, 2026.
- Previously disclosed results showed high complete response rates and durable remissions in second-line and later-line relapsed or refractory large B-cell lymphoma.
- No severe cytokine release syndrome occurred in either cohort; severe neurotoxicity was uncommon, supporting potential outpatient administration.
- The pivotal PiNACLE trial is intended to support an initial application for regular marketing approval.
- A separate randomized Phase 3 trial compares ronde-cel with approved CD19-directed CAR T-cell therapies in second-line treatment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
